Join Growin Stock Community!

Design therapeutics, inc.DSGN.US Overview

US StockHealthcare
(No presentation for DSGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DSGN AI Insights

DSGN Overall Performance

DSGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DSGN Recent Performance

-3.54%

Design therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

DSGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DSGN Key Information

DSGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DSGN Profile

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Price of DSGN

DSGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DSGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
22642.01
PB Ratio
2.98
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
22642.01
PB Ratio
2.98
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is DSGN's latest earnings report released?

    The most recent financial report for Design therapeutics, inc. (DSGN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DSGN's short-term business performance and financial health. For the latest updates on DSGN's earnings releases, visit this page regularly.

  • How much cash does DSGN have?

    At the end of the period, Design therapeutics, inc. (DSGN) held Total Cash and Cash Equivalents of 15.09M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is DSGN's EPS continuing to grow?

    According to the past four quarterly reports, Design therapeutics, inc. (DSGN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DSGN?

    Design therapeutics, inc. (DSGN)'s Free Cash Flow (FCF) for the period is -11.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 17.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.